It has gradually become clear that insight is involved in the cancer growth and regulation. Insulin Growth Factor Receptor(IGFR) is important in this process. IGF-IR blockaded by IMC-A12 results in rapid and profound growth inhibition of cancers of the breast, lung, colon, and pancreas, and many other cancers. Although promising single-agent activity has been observed, the most impressive effects of targeting the IGF-IR with IMC-A12 have been noted when this agent was combined with cytotoxic agents or other targeted therapeutics. So far, only a few preliminary human studies had been published, including in Ewing sarcoma. This drug may also have applications in auto-immune disorders. It remains an experimental drug.
Read the Professional version here.